Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Inc. (TSXV:HEM) shares second stem cell recipient interview results

Caroline Egan  October 4, 2021

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain

Newsfile October 4, 2021

Hemostemix (TSXV:HEM) closes the first tranche of its private placement

John Ballem  September 21, 2021

Hemostemix Announces Closing of First Tranche of Unit Private Placement

Newsfile September 21, 2021

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Newsfile September 14, 2021

Hemostemix Announces Five Million Unit Private Placement

Newsfile September 8, 2021

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results

Newsfile July 6, 2021

Hemostemix Announces Warrant Repricing and Extension

Newsfile July 5, 2021

Peter Lacey Increases His Investment in Hemostemix Inc.

Newsfile June 21, 2021

Hemostemix (TSXV:HEM) closes $2,500,000 convertible debenture

John Ballem  June 11, 2021

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture

Newsfile June 11, 2021

Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record

Newsfile May 31, 2021

Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update

Newsfile May 29, 2021

Hemostemix to Present at the Emerging Growth Conference

Newsfile May 25, 2021

Hemostemix Announces Closing of Unit Private Placement

Newsfile May 10, 2021

Hemostemix Announces Warrant Repricing and Extension

Newsfile May 6, 2021

Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

Newsfile April 30, 2021

Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering

Newsfile April 26, 2021

Hemostemix (TSXV:HEM) announces completion of Phase II clinical trial subject follow up

Simon Druker  April 23, 2021

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

Newsfile April 23, 2021